EA2222 (Colorectal Cancer with Liver Metasases) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if infusing chemotherapy drugs directly into the hepatic artery (the blood vessel that supplies blood to the liver) is a better treatment option than standard chemotherapy for people who have colorectal cancer that has spread to the liver.

What is the Condition Being Studied?

Colorectal Cancer That Has Metastasized to the Liver

Who Can Participate in the Study?

Adults ages 18+ who:

  • Are diagnosed with unresectable colorectal cancer
  • Have metastases to the liver
  • Have received a 3-6 month course of previous first-line chemotherapy
  • Have not received radiation therapy directed toward the liver

For more information about who can join this study, please contact the study team at nick.jeffries@duke.edu.

Age Group

What is Involved?

If you choose to join this study, you will get a random assignment (like a coin flip) to 1 of 2 groups:

  • Group 1 will get will get chemotherapy that's given in the traditional manner and directly into the hepatic artery
  • Group 2 will get will get chemotherapy that's given in the traditional manner only

Study Details

Full Title
EA2222: A Randomized Phase III Study of Systemic Therapy With or Without Hepatic rterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00114675
NCT: NCT05863195
Phase III
Enrollment Status
Open for Enrollment